ストックスクリーナーアプリを入手
16.27
1.45%
-0.24
前日終値:
$16.51
開ける：
$16.66
24時間の取引高:
1.19M
Relative Volume:
0.76
時価総額：
$2.54B
収益：
$340.81M
当期純損益:
$-419.65M
株価収益率:
-5.7088
EPS:
-2.85
ネットキャッシュフロー:
$-402.10M
1週間 パフォーマンス:
-3.56%
1か月 パフォーマンス:
-8.80%
6か月 パフォーマンス:
+9.19%
1年 パフォーマンス:
-21.93%
1日の値動き範囲:
$15.69
$16.68
1週間の範囲:
$15.69
$16.91
52週間の値動き範囲:
$10.57
$24.34
Denali Therapeutics Inc Stock (DNLI) Company Profile
名前
Denali Therapeutics Inc
セクター
電話
(650) 866-8547
住所
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
DNLI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
16.27 | 2.58B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-10 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2025-03-07 | 再開されました | Morgan Stanley | Overweight |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2025-01-07 | 開始されました | Robert W. Baird | Outperform |
| 2025-01-03 | 開始されました | William Blair | Outperform |
| 2024-12-16 | アップグレード | Stifel | Hold → Buy |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-10-07 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | 開始されました | Citigroup | Buy |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-09-06 | 開始されました | B. Riley Securities | Buy |
| 2023-01-30 | 開始されました | SVB Securities | Outperform |
| 2022-12-05 | 開始されました | Cowen | Outperform |
| 2022-11-02 | アップグレード | BTIG Research | Neutral → Buy |
| 2022-11-02 | 開始されました | BofA Securities | Buy |
| 2022-06-23 | 開始されました | Berenberg | Buy |
| 2021-12-10 | 再開されました | Raymond James | Mkt Perform |
| 2021-09-21 | 開始されました | Oppenheimer | Outperform |
| 2021-09-01 | 開始されました | SMBC Nikko | Outperform |
| 2021-05-18 | 開始されました | UBS | Buy |
| 2021-02-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-02-10 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-16 | ダウングレード | BTIG Research | Buy → Neutral |
| 2020-09-14 | 再開されました | JP Morgan | Overweight |
| 2020-08-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-13 | アップグレード | Evercore ISI | In-line → Outperform |
| 2020-02-28 | アップグレード | Wedbush | Neutral → Outperform |
| 2020-02-24 | 開始されました | Jefferies | Buy |
| 2020-02-19 | 開始されました | Stifel | Hold |
| 2020-01-27 | アップグレード | Goldman | Neutral → Buy |
| 2019-09-26 | 開始されました | Wedbush | Neutral |
| 2019-09-13 | 開始されました | Nomura | Buy |
| 2019-08-09 | 開始されました | BTIG Research | Buy |
| 2019-06-26 | 開始されました | H.C. Wainwright | Buy |
| 2018-11-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-11-12 | 開始されました | Janney | Buy |
| 2018-03-12 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2018-01-02 | 開始されました | Evercore ISI | Outperform |
| 2018-01-02 | 開始されました | Goldman | Neutral |
| 2018-01-02 | 開始されました | JP Morgan | Overweight |
| 2018-01-02 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Denali Therapeutics Inc (DNLI) 最新ニュース
Hunter Syndrome Treatment Market is expected to reach US$ - openPR.com
Denali’s Hunter syndrome therapy shows promise in Phase 1/2 trial - Investing.com Nigeria
Understanding Momentum Shifts in (DNLI) - Stock Traders Daily
Denali Therapeutics stock holds Buy rating at Jefferies on FDA approval confidence - Investing.com Nigeria
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II) - The Manila Times
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II) - GlobeNewswire Inc.
Towards 2026, Focusing on Three High-Potential Biotechnology Companies - NAI500
3 Biotech Stocks With Major 2026 Catalysts - Nasdaq
Denali Therapeutics clears technical benchmark, hitting 80-plus RS rating - MSN
What drives Denali Therapeutics Inc 4DN stock priceIPO Market Watch & Free Expert Stock Watchlists - earlytimes.in
Denali Therapeutics Earnings Notes - Trefis
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
BTIG reiterates Denali Therapeutics (DNLI) buy recommendation - MSN
Denali Therapeutics (DNLI): Assessing Valuation After $200 Million Secondary Offering and FDA Voucher Discussions - Yahoo Finance
How Investors May Respond To Denali Therapeutics (DNLI) $200 Million Equity Raise And FDA Voucher Talks - Yahoo Finance
Is Denali Therapeutics (DNLI) the Most Promising Mid-Cap Healthcare Stock Under $50? - Insider Monkey
Denali Therapeutics announces $200M proposed offering of common stock and pre-funded warrants - MSN
What risks investors should watch in Denali Therapeutics Inc. stockWeekly Risk Report & Free Community Supported Trade Ideas - Улправда
15 Most Promising Mid-Cap Healthcare Stocks Under $50 - Insider Monkey
Is Denali Therapeutics Inc. stock a good choice for value investorsWeekly Volume Report & Expert Curated Trade Setup Alerts - Улправда
Precision Trading with Denali Therapeutics Inc. (DNLI) Risk Zones - Stock Traders Daily
Analyst Downgrade: Will Denali Therapeutics Inc. stock reach all time highs in 2025Weekly Market Report & Daily Stock Trend Watchlist - Улправда
Is Denali Therapeutics Inc. stock positioned for digital transformation2025 Market Trends & Daily Volume Surge Signals - Улправда
What insider trading reveals about Denali Therapeutics Inc. stock2025 AllTime Highs & Fast Gain Swing Alerts - Улправда
Can Denali Therapeutics Inc. (4DN) stock sustain institutional flowsQuarterly Trade Summary & Free Risk Controlled Daily Trade Plans - Улправда
What dividend safety score for Denali Therapeutics Inc. stockJuly 2025 Big Picture & High Accuracy Investment Signals - DonanımHaber
Is Denali Therapeutics Inc. (4DN) stock a good hedge against inflationEarnings Growth Summary & Low Risk High Win Rate Picks - DonanımHaber
Is Denali Therapeutics Inc. stock recession proof2025 Support & Resistance & Detailed Earnings Play Strategies - DonanımHaber
What Wall Street predicts for Denali Therapeutics Inc. stock priceEarnings Miss & AI Enhanced Trading Alerts - DonanımHaber
What catalysts could drive Denali Therapeutics Inc. stock higherFed Meeting & Technical Buy Zone Confirmations - Улправда
Does Denali Therapeutics' (DNLI) Discounted Equity Raise Reveal a New Phase in Its Risk Strategy? - simplywall.st
Revenue per share of Denali Therapeutics Inc. – DUS:4DN - TradingView — Track All Markets
Beyond Weight Loss: The "Cellular Reset" That Could Create the Next Biotech Supercycle - The Globe and Mail
Denali Therapeutics (DNLI) funds add $0.01 prefunded warrants in public offering - Stock Titan
Marex Group plc Takes $3.67 Million Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Camber Capital Management LP Has $5.60 Million Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Will Denali's Expanding Pipeline Deliver Breakthroughs In Neurodegenerative Medicine? - RTTNews
Wedbush Issues Pessimistic Forecast for Denali Therapeutics (NASDAQ:DNLI) Stock Price - MarketBeat
Wedbush Maintains 'Outperform' Rating for DNLI, Lowers Price Tar - GuruFocus
Wedbush Trims Price Target on Denali Therapeutics to $30 From $31, Keeps Outperform Rating - marketscreener.com
Denali Therapeutics prices stock offering at $17.50 per share - MSN
Goodwin Advised Royalty Pharma In $275 Million Royalty Funding Agreement With Denali Therapeutics - Mondaq
Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment (DNLI) - Seeking Alpha
Denali Therapeutics (NASDAQ:DNLI) Shares Gap DownHere's What Happened - MarketBeat
Denali Therapeutics dips after pricing $200M equity offering - MSN
Denali Therapeutics Prices $200 Million Public Offering - marketscreener.com
Denali Therapeutics Inc (DNLI) 財務データ
収益
当期純利益
現金流量
EPS
Denali Therapeutics Inc (DNLI) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Schuth Alexander O. | COFO and Secretary |
Aug 12 '25 |
Sale |
13.58 |
2,937 |
39,884 |
242,346 |
| Ho Carole | Chief Medical Officer |
Aug 12 '25 |
Sale |
13.58 |
2,937 |
39,884 |
217,391 |
| Ho Carole | Chief Medical Officer |
Aug 13 '25 |
Sale |
14.64 |
806 |
11,800 |
216,585 |
0.57%
大文字化:
|
ボリューム (24 時間):